Watching the Barn Door Open-Timing CML Stem Cell Allografts.
作者信息
Lipton Jeffrey H
机构信息
Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
出版信息
Am J Hematol. 2025 Aug;100(8):1268-1270. doi: 10.1002/ajh.27722. Epub 2025 May 20.
Abstract
摘要
相似文献
1
Watching the Barn Door Open-Timing CML Stem Cell Allografts.
Am J Hematol. 2025 Aug;100(8):1268-1270. doi: 10.1002/ajh.27722. Epub 2025 May 20.
2
We do still transplant CML, don't we?
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):177-184. doi: 10.1182/asheducation-2018.1.177.
3
Reconstitution of NK cells expressing KIR3DL1 is associated with reduced NK cell activity and relapse of CML after allogeneic hematopoietic stem cell transplantation.
Int J Hematol. 2020 May;111(5):733-738. doi: 10.1007/s12185-019-02809-5. Epub 2019 Dec 23.
4
Stem cell transplantation in patients with chronic myelogenous leukemia: when should it be used?
Mayo Clin Proc. 2006 Mar;81(3):404-16. doi: 10.4065/81.3.404.
5
What is the best strategy for C3 in open-door laminoplasty: laminectomy versus laminoplasty-a systematic review and meta-analysis.
Spine J. 2025 Jul;25(7):1440-1454. doi: 10.1016/j.spinee.2025.01.034. Epub 2025 Jan 31.
6
CML stem cells and their interactions and adaptations to tyrosine kinase inhibitors.
Leuk Lymphoma. 2025 Jul;66(7):1211-1220. doi: 10.1080/10428194.2025.2466817. Epub 2025 Mar 2.
7
Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry.
Bone Marrow Transplant. 2019 Nov;54(11):1764-1774. doi: 10.1038/s41409-019-0513-5. Epub 2019 Apr 8.
8
[Allo-geneic hematopoietic stem cell transplantation in treatment with T315I mutation of chronic myelogenous leukemia].
Zhonghua Yi Xue Za Zhi. 2014 Nov 4;94(40):3150-3.
9
Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation.
Case Rep Hematol. 2011;2011:263725. doi: 10.1155/2011/263725. Epub 2011 Nov 3.
10
Chronic myeloid leukemia, tyrosine kinase inhibitors and cardiovascular system.
Eur Rev Med Pharmacol Sci. 2023 Jun;27(12):5493-5506. doi: 10.26355/eurrev_202306_32786.
本文引用的文献
1
Evolution of Allogeneic Stem Cell Transplantation: Main Focus on AML.
Cells. 2025 Apr 10;14(8):572. doi: 10.3390/cells14080572.
2
Assessment of Survivorship in Allogeneic Hematopoietic Stem Cell Transplantation.
Methods Mol Biol. 2025;2907:91-125. doi: 10.1007/978-1-0716-4430-0_5.
3
Chronic Myeloid Leukemia: A Review.
JAMA. 2025 May 13;333(18):1618-1629. doi: 10.1001/jama.2025.0220.
4
Living, not just surviving, with chronic myeloid leukemia - quality of life to the front of the line.
Leukemia. 2025 May;39(5):1056-1057. doi: 10.1038/s41375-025-02548-z. Epub 2025 Mar 5.
5
Novel treatment strategies for chronic myeloid leukemia.
Blood. 2025 Feb 27;145(9):931-943. doi: 10.1182/blood.2024026312.
6
Understanding and overcoming resistance to tyrosine kinase inhibitors (TKIs) in Chronic myeloid leukemia (CML).
Expert Rev Hematol. 2025 Jan;18(1):65-79. doi: 10.1080/17474086.2024.2440776. Epub 2024 Dec 15.
7
Loss in Overall and Quality-Adjusted Life Expectancy for Patients With Chronic-Phase Chronic Myeloid Leukemia.
Eur J Haematol. 2025 Feb;114(2):334-342. doi: 10.1111/ejh.14328. Epub 2024 Nov 6.
8
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw. 2024 Feb;22(1):43-69. doi: 10.6004/jnccn.2024.0007.
9
Stem cell allografting for chronic Myeloid leukemia in the tyrosine kinase era - forgotten but not gone.
Leuk Lymphoma. 2024 Jun;65(6):705-714. doi: 10.1080/10428194.2024.2313626. Epub 2024 Feb 9.
10
Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option.
Blood Rev. 2022 Nov;56:100968. doi: 10.1016/j.blre.2022.100968. Epub 2022 May 6.
Zotero 插件